Genus PLC
29 April 2008

For Immediate Release 29 April 2008

GENUS plc
('Genus' or 'the Company')

Interim Management Statement

Genus, a leading global animal genetics company, today publishes its interim management statement for the period 1 January 2008 to 28 April 2008.

Trading Performance

Genus continues to trade in line with the Board's expectations.

The dairy semen business has remained strong and Genus has experienced a growing demand for sexed semen as farmers increasingly seek to improve output from their dairy herds.

Market conditions for the Genus' non-dairy customers remain challenging with pig and beef slaughter prices still not reflecting the substantial increases in feed prices that are being experienced. However, the demand for meat remains strong, particularly for pork in high growth regions, and we therefore expect global slaughter prices to rise in due course. In the meantime, the Company's royalty model within its porcine business continues to protect profitability, especially in North America, limiting Genus' exposure to the hog cycle.

Material Events

On 15 January 2008 the Company completed the disposal of its non-core veterinary pharmaceutical business, Animalcare Limited, for a total cash consideration of Â£13.4m.

Financial Position

The net debt position of the Company as at 31 March 2008 was reduced to Â£82m (31 December 2007: Â£93m) with the Company switching Â£30m of this debt into US$ as part of its hedging policy during the period under review.

There have been no other significant changes in the financial position of the Company since the publication of the Interim Financial Report for the six month period ended 31 December 2007.

Outlook

The trading outlook of the Company for the remainder of the financial year continues to be in line with the Board's expectations. Genus expects to announce its preliminary results for the year ending 30 June 2008 on 16 September 2008.

For further information please contact:

Genus plc Tel: 01256 345970
Richard Wood, Chief Executive
Martin Boden, Finance Director

Buchanan Communications Tel: 020 7466 5000
Charles Ryland/Suzanne Brocks

About Genus

Genus sells added value products for livestock farming and food producers by

creating advances to animal breeding through biotechnology. Its non genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trade marks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers use Genus genetics in their herds to produce offspring with greater production efficiency, milk and meat output and quality. These offspring are used to supply the global dairy and meat supply chain.

Genus' competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in Basingstoke, England, Genus companies operate in 30 countries on six continents, with research laboratories located in Madison, USA.

This information is provided by RNS
The company news service from the London Stock Exchange